Redeye comments on Lytix' Q3 report. The main event since our last update is the start of the NeoLIPA trial, a study of LTX-315 as neoadjuvant melanoma treatment.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/